Novavax reports Q4 EPS 11c vs. (51c) last year

Reports Q4 revenue $147M, consensus $89.86M. “In 2025, we made significant progress on our corporate strategy, marked with the successful achievement of key milestones under our Sanofi agreement, progress towards potential new partnerships, in the form of multiple MTAs signed with other parties enabling experimentation with our Matrix-M adjuvant technology and the advancement of our own R&D efforts,” said John C. Jacobs, President and CEO, Novavax (NVAX). “With a strong start to 2026, including the recently announced Pfizer Matrix-M agreement, we look forward to commercial and clinical development execution from our partners, advancing our R&D efforts and the potential for more partnerships as we drive vaccine innovation and value creation from our technology.”